Company intelligence / Profile preview

Volition

Austin, Texas, United Statesvolition.com ↗

Ownership: Public · VNRX
Employees: ~80
Development stage: Commercial

Overview

Volition is advancing epigenetic diagnostics with a focus on early detection and monitoring of diseases like cancer and sepsis using blood tests. Their Nu.Q® platform is being commercialized for both human and veterinary applications.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Blood-based assaysLiquid biopsy immunoassay
Industry: Protein Biomarker Diagnostics

Drug pipeline

3 assets

Nu.Q NETs

Commercial

Indications: NETosis, Sepsis

2 more assets in the full pipeline.

Request access →

Partnerships

Various academic institutionspharmaceutical companies

Financials

Market cap: $2.9M
Total revenue: $398.7K
Enterprise value: $12M

Beyond the preview

Go deeper on Volition.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Volition.

Explore the full profile